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Patients
Fig. 1. Age and sex distribution of patients entering the
trial.
quential analysis chart; only posItive preferences for one
drug or the other were recorded, and comparisons show·





















Seventy-nine patients with classical or definite rheumatoid
arthritis' entered the trial. None of the patients had taken
systemic steroids during the previous 2 years, and only 4
had been on steroids at any time during the course of their
disease. The age and sex distribution are shown in Fig. 1.
The distribution of patients in the 3 trial groups is shown
in Table 1.
S. Afr. Med. J., 48, 949 (1974).
GP 45'840 waS compared with three different prepara-
tions: (i) placebo; (ii) paracetamol, and (iii) acetylsalicylic
acid. It was intended that this should assess the over-all
efficacy and also distinguish the simple analgesic from the
combined analgesic and anti-inflammatory properties of
the test drug.
Each section of the trial was carried out by a double-
blind crossover method using the two drugs consecutively
in the same patient. Global results were plotted on a se-
Trial Design
A double-blind, crossover trial of a new non-steroidal,
anti-inflammatory drug has been carried out in 79 patients
with rheumatoid arthritis. The preparation, GP 45'840
(Voltaren), was tested against placebo, paracetamol, and
high dosage acetylsalicylic acid. It was superior to placebo
and paracetamol at a statistically significant level
(P<0,05).
On both objective and subjective criteria its actions
were similar to those of high dosage salicylate. Side-
effects, however, were markedly less than with either
paracetamol or salicylate, which contributed to the fact
that most of the patients who completed the trial preferred
the new preparation.
It was concluded that GP 45'840 has significant anti-
inflammatory and analgesic actions in patients with rheu-




The oral preparation of GP 45'840 (Voltaren) is completely
absorbed from the gastro-intestinal tract and causes little
irritation of the gastro-intestinal mucosa. Maximum plasma
concentration is reached after 1 . 4 hours. After absorption
it is rapidly and completely excreted. During the first 12
hours after oral and intravenous administration 40% of
the administered dose is found in the urine; after 72
hours the excretion is almost complete.-
A short pilot study by one of us (L.S.) showed that the
drug was effective in patients with rheumatoid arthritis
(RA), and suggested that a full clinical trial was warranted.
Department of Orthopaedic Surgery, Medical School,
University of the Witwatersrand, Johannesburg
L. SOLOMO.I, M.B. CH.B., F.R.C.S., M.D.
G. ABRAMS, M.B. B.CR.
Date received: 11 October 1973.
Drug Administration
The two trial medications in each group were presented
in identical form and administered 4 times a day after
meals and after an evening snack. The daily dosages are
-
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TABLE I. DISTRIBUTION OF PATIENTS IN THE 3 TRIAL
GROUPS
GP 45'840 GP 45'840
during during
first second
Trial group period period Total
GP 45'840 vs placebo 10 10 20
GP 45'840 vs 17 18 35
paracetamol
GP 45'840 vs salicylate 12 12 24
shown in Table n. The sequence of drug administration
was suitably randomised. After a wash-out period during
which the patient received no medication whatever, each
drug was given for 7 consecutive days, the crossover
occurring without a further wash-out period. No other
analgesic or anti-inflammatory preparations were permitted
during the trial period.
Over-all superiority of one drug over the other was
indicated by an appropriate breakthrough on the sequen-
tial analysis chart.
RESULTS
GP 45' 840 versus Placebo
Of the 20 patients in this section of the trial, 10 re-
ceived GP 45'840 as the first and placebo as the second
drug, and IQ vice versa. Three patients dropped out of
the trial, 2 for reasons unrelated to the treatment, and one
because of intense headaches and insomnia which he
developed while on placebo.
The global preference based on the combination of
objective criteria is represented in the sequential analysis
chart (Fig. 2); GP 45'840 showed a statistically significant
superiority over placebo (P<0,05).
Significance probability 2:< = 0.1
Fig. 2. Sequential analysis; GP 45'840 versus placebo.
Note rapid breakthrough in favour of GP 45'840.
The individual criteria were also assessed separately.
o difference in joint circumferences was detected in the
two treatment sequences. GP 45'840 was significantly
superior to placebo in improving the 'ability to walk' (P<
0,(5). In all the other parameters GP 45'840 was superior
to placebo, but this did not reach the level of statistical
significance.
Ten patients complained of side-effects while being
treated with placebo, and 6 of side-effects during the
GP 45'840 treatment period. Gastro-intestinal symptoms

















Time GP 45'840 Paracetamol Salicylate
Breakfast 50 1500 1250
Lunch 25 1500 1 250
Dinner 25 1500 1250
Evening 50 1500 1 250
Total 1,50 6000 5000
Assessment
TABLE 11. DAILY DOSAGES (IN mg) OF DRUGS
ADMINISTERED
Assessments were carried out after the wash-out period
and subsequently after each 7-day treatment period. Assess-
ment was based on three principal criteria: the articular
index of pain, grip strength and measurement of joint
circumference.
Articular index: Joint tenderness was scored on a 4-
point scale (0-1-2-3) after the method of Ritchie et al.'
All joints were tested whether the patient complained of
symptoms or not.
Grip strength was measured for each hand on an ordin-
ary sphygmomanometer cuff inflated to 30 mmHg; the
result of a single firm squeeze was recorded and the values
for the two hands added for the final figure.3
Joint circumference was measured at the proximal inter-
phalangeal joint of each finger and the values for the 10
digits added together for the final figure.
Subjective evaluation: In addition to these objective
methods, the patient was asked to record his own evalua-
tion of the following parameters on simple linear scales:
degree of pain; degree of early morning stiffness; ability
to walk and global feeling of well-being.
Finally the investigator's preference for either week 1 or
week 2 medications (established by a simple majority of
the principal criteria in favour of one or other), was sub-
jected to a sequential analysis.
Fig. 3. Sequential analysis: GP 45'840 versus paracetamol.
GP 45'840 versus Acetylsalicylic Acid
Thirty-five patients entered this section of the trial;
17 received GP 45'840 as the first drug, and 18 received
paracetamol as the first drug. Nine patients dropped out,
3 for reasons unrelated to the trial, and 6 because of
side-effects associated with paracetamol.
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Significance probability 2cx = 0.2
Fig. 4. Sequential analysis: GP 45'840 versus salicylate.
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DISCUSSION
The two prime requirements in the choice of drugs for
the long-term treatment of RA are that they should have
a demonstrable anti-inflammatory effect, and that they
should produce the minimum of unpleasant side-effects.
The results of the present trial suggest that GP 45'840 has
analgesic and anti-inflammatory actions superior to those
of paracetamol and equal to those of salicylate in high
dosage.
Conducting the trial as an inpatient, crossover assess-
ment during a relatively short period reduces the likeli-
hood that the results were influenced by natural fluctua-
tions in disease activity and variations between different
patients. Since it is recognised that the order in which the
drugs are given might also influence the results during
each trial period, the order of administration was appro-
priately randomised.
ference slightly favoured GP 45'840 (Fig. 4). Response to
treatment as assessed by changes in the degree of pain,
early-morning stiffness, ability to walk and over-all feeling-
of well-being. The common and adjusted means, obtained
by analysis of covariance, after 1 week and 2 weeks of
medication, thus provided a treatment profile. Further
analysis gave variance ratios in the order of 1 in all
parameters, indicating negligible differences between the
treatments. Analysis of both the investigators' and patients'
global preferences supported this observation.
Eighteen of the 24 patients who started the trial deve-
loped side-effects while on salicylate; 15 had tinnitus or
deafness and 9 had gastro-intestinal symptoms. Seven
patients complained of side-effects while on GP 45'840; 3
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GP 45'840 versus Paracetamol
There were 24 patients in this section, 12 of whom
received GP 45'840 as the first drug in the sequence.
Three patients dropped out of the trial, 2 for reasons
unrelated to the drugs administered and 1 because of
severe nausea and tinnitus attributed to salicylate.
In this group there was no breakthrough on the
sequential analysis chart though the investigator's pre-
10
A breakthrough on the sequential analysis chart indi-
cated that GP 45'840 was significantly (P<0,05) superior to
paracetamol in the over-all objective assessment (Fig. 3).
Of the individual criteria, joint circumference showed no
difference in the two treatment sequences; grip strength
indicated superiority for GP 45'840, though this did not
reach statistical significance; the remaining parameters all
showed statistically significant superiority for GP 45'840
(P<O,OOI - 0,025).
Of the 26 patients who completed the trial, 11 com-
plained of side-effects while receiving paracetamol, and 6
had side-effects on GP 45'840. Gastro-intestinal symptoms
occurred in 6 patients on paracetamol and in 1 patient
on GP 45'840.
15
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TABLE Ill. SIDE-EFFECTS OF GP 45'840 (64 PATIENTS)
It is well known that the clinical features of inflamma-
tory polyarthritis may be lessened by effective analgesia,
which increases the range of motion of individual joints
and the over-all activity of the patient. For this reason the
trial drug was tested separately against an analgesic
and a known anti-inflammatory drug in the form of high-
dosage salicylate. In both cases GP 45'840 produced a
response at least as good as that with the comparative
drug; as might be expected it was markedly superior to
a placebo preparation.
On the second criterion, the incidence of side-effects,
GP 45'840 was preferred over the comparative drug in





















with GP 45'840, 19 complained of side-effects (Table Ill).
In all but 3 cases, however, these were mild and transient,
and in no instance did the patient stop taking the drug
on this account. The commonest symptom noted was
nausea, which occurred in 6 cases and was described as
severe in 2 instances. It is noteworthy that 6 patients also
complained of nausea while on placebo! Gastro-intestinal
symptoms (apart from nausea) were seldom troublesome
during treatment with GP 45'840 (2 cases out of 64), but
occurred in 12 patients while receiving one of the other
preparations.
In addition to the clinical assessment described, the sub-
jective opinion of the patient was solicited in each trial.
There was a reasonably close correlation between these
results and the results of the objective evaluation. In some
cases, however, it was clear that the patient's preference
was detemlined as much by an aversion to the side-
effects of one drug as by a positive response to the other.
Supplies of GP 45'840 and matched drugs used in the trial
were provided by Ciba-Geigy (Pty) Ltd.
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